Physician profile
Ryan M Bauer
NPI 1457589368
$5,691.37
in general payments reported to CMS, 2019-2025
18 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $450 · 2021: $410 · 2022: $768 · 2023: $634 · 2024: $776 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,894 · Entertainment: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,893.56 |
| Entertainment | $309.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,346.58 | 2019-2025 | Acuvue |
| Coopervision INC. | $1,078.92 | 2020-2025 | Misight Contact Lens, Myday Contact Lens, Onefit Contact Lens |
| Alcon Vision LLC | $1,034.61 | 2019-2025 | Precision7, Precision 1, Tryptyr |
| Optos, INC. | $367.19 | 2019-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $341.64 | 2022-2025 | Infuse, Infuse Multifocal |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $267.20 | 2019-2021 | |
| Shire North American Group INC | $202.66 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $163.19 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $143.64 | 2022 | |
| Sun Pharmaceutical Industries INC. | $119.57 | 2025 | |
| Lombart Brothers, INC. | $99.17 | 2025 | Opd-III |
| Astellas Pharma US INC | $97.41 | 2024 | Izervay |
| Lkc Technologies, INC. | $92.61 | 2024 | |
| Abb Con-Cise Optical Group LLC | $90.69 | 2019-2020 | |
| Optovue, INC. | $80.47 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $73.11 | 2019 | |
| Eyevance Pharmaceuticals LLC | $62.02 | 2019 | |
| Biotissue Holdings INC. | $30.69 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.